Pioneering biogenerics

Learn more about our state-of-the-art biosimilar facility

Explore

Company

Who we are

Alvotech is a privately owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal ...

Read more

Research and development

WHAT WE DO

Our vision as a company is to build a leading global biopharmaceutical company, while focusing on the development, and the commercialization of medicines for the treatment of severe, immune, inflammatory conditions. 

Read more

Newsroom

Alvotech enrolls first patient in clinical phase III study

Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA®

  • Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors

Read More

Meet management

World Class team

Our organizational structure is effective, flexible and has a proven track record that will enable the company to bring new biopharmaceutical products quickly and safely to market. The leadership team is helmed by Rasmus Rojkjaer.

Leadership team

Partnerships

Partnering with Alvotech is gaining access to high quality, ready to market biosimilars


More

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.